<DOC>
	<DOCNO>NCT02467270</DOCNO>
	<brief_summary>The purpose study compare characterize efficacy safety ponatinib patient resistant chronic myeloid leukemia ( CML ) chronic phase ( CP ) range dos .</brief_summary>
	<brief_title>Ponatinib Patients With Resistant Chronic Phase Chronic Myeloid Leukemia ( CML ) Characterize Efficacy Safety Range Doses</brief_title>
	<detailed_description>This multi-center , randomize , phase 2 trial characterize safety efficacy ponatinib range 3 starting dos . Eligible patient must chronic phase chronic myeloid leukemia ( CP-CML ) resistant least 2 tyrosine kinase inhibitor ( TKIs ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>1 . Have CPCML resistant least two prior TKIs 2 . Be male female patient ≥18 year old 3 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 4 . Have adequate renal function define follow criterion : Serum creatinine ≤1.5 × upper limit normal ( ULN ) institution 5 . Have adequate hepatic function define follow criterion : Total serum bilirubin ≤1.5 × ULN , unless due Gilbert 's syndrome Alanine transaminase ( ALT ) ≤2.5 × ULN , ≤5 × ULN leukemic involvement liver present Aspartate transaminase ( AST ) ≤2.5 × ULN , ≤5 × ULN leukemic involvement liver present 1 . Have use approve TKIs investigational agent within 2 week 6 halflives agent , whichever longer , prior receive study drug 2 . Received interferon , cytarabine , immunotherapy within 14 day , cytotoxic chemotherapy , radiotherapy , investigational therapy within 28 day prior receive first dose ponatinib , recover ( &gt; grade 1 NCI Common Toxicity Criteria Adverse Effects ( CTCAE ) , version 4.0 ) AEs ( except alopecia ) , due agent previously administer 3 . Have undergone autologous allogeneic stem cell transplant &lt; 60 day prior receive first dose ponatinib ; evidence ongoing graftversushost disease ( GVHD ) GVHD require immunosuppressive therapy consider stem cell transplant within 612 month enrollment ( note : ponatinib use bridge stem cell transplant trial ) 4 . Are take medication know risk Torsades de Pointes 5 . Have clinically significant , uncontrolled , active cardiovascular disease , specifically include , restrict : Any history myocardial infarction ( MI ) , unstable angina , cerebrovascular accident , Transient Ischemic Attack ( TIA ) Any history peripheral vascular infarction , include visceral infarction Any revascularization procedure , include placement stent Congestive heart failure ( NYHA class III IV ) within 6 month prior enrollment , leave ventricular ejection fraction ( LVEF ) less low limit normal , per local institutional standard , within 6 month prior enrollment History clinically significant ( determined treat physician ) atrial arrhythmia history ventricular arrhythmia Venous thromboembolism , include deep venous thrombosis pulmonary embolism , within 6 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Phase Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>CP-CML</keyword>
</DOC>